Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)

[1]  A. Grossman,et al.  Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression , 2016, Endocrinology.

[2]  V. Fendrich,et al.  Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1 , 2016, World Journal of Surgery.

[3]  R. Iyer,et al.  Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors , 2016, Current Oncology Reports.

[4]  P. Ruszniewski,et al.  Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.

[5]  C. Schade-Brittinger,et al.  Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.

[6]  J. Strosberg,et al.  The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors , 2015, Drugs.

[7]  D. Coppola,et al.  Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. , 2014, Endocrine-related cancer.

[8]  B. Elmunzer,et al.  Long-term Follow-up of Asymptomatic Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type I Syndrome , 2013, Journal of clinical gastroenterology.

[9]  B. Skogseid,et al.  Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model. , 2013, The American journal of pathology.

[10]  S. Libutti,et al.  Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. , 2012, Surgery.

[11]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[12]  M. Falconi,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.

[13]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[14]  A. Tabarin,et al.  Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients , 2010, World Journal of Surgery.

[15]  B. Harding,et al.  Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia , 2009, Endocrine-related cancer.

[16]  M. Korbonits,et al.  Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.

[17]  G. Feldmann,et al.  Hedgehog signaling is required for effective regeneration of exocrine pancreas. , 2008, Gastroenterology.

[18]  E. Baudin,et al.  Prospective Endoscopic Ultrasonographic Evaluation of the Frequency of Nonfunctioning Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1 , 2006, The American Journal of Gastroenterology.

[19]  J. Chayvialle,et al.  Epidemiology Data on 108 MEN 1 Patients From the GTE With Isolated Nonfunctioning Tumors of the Pancreas , 2006, Annals of surgery.

[20]  J. Carney,et al.  Familial Multiple Endocrine Neoplasia: The First 100 Years , 2005, The American journal of surgical pathology.

[21]  A. Gozzini,et al.  Multiple endocrine neoplasia type 1 , 2006, Orphanet journal of rare diseases.

[22]  Zhao-Qi Wang,et al.  Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. , 2003, Molecular endocrinology.

[23]  M. Papotti,et al.  Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors , 2002, Virchows Archiv.

[24]  W. Simonds,et al.  Multiple endocrine neoplasia type 1: new clinical and basic findings , 2001, Trends in Endocrinology & Metabolism.

[25]  N. Vaysse,et al.  Antiproliferative Effect of Somatostatin and Analogs , 2001, Chemotherapy.

[26]  J. Mulvihill,et al.  The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. , 1998, Surgery.

[27]  L. Liotta,et al.  Multiple Endocrine Neoplasia Type 1: Clinical and Genetic Topics , 1998, Annals of Internal Medicine.

[28]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[29]  C. Edwards,et al.  Clinical studies of multiple endocrine neoplasia type 1 (MEN1) , 1996, QJM : monthly journal of the Association of Physicians.